scispace - formally typeset
M

Masaomi Yamasaki

Researcher at St. Marianna University School of Medicine

Publications -  6
Citations -  449

Masaomi Yamasaki is an academic researcher from St. Marianna University School of Medicine. The author has contributed to research in topics: Dermatomyositis & Polymyositis. The author has an hindex of 5, co-authored 6 publications receiving 402 citations.

Papers
More filters
Journal ArticleDOI

Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis

TL;DR: In this open-label study, IVCYC improved symptoms, pulmonary function tests and HRCT findings in patients with PM/DM and longitudinal controlled studies are required to further confirm the efficacy and safety ofIVCYC.
Journal ArticleDOI

Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan.

TL;DR: Survival of clinically ADM and primary DM was low, mainly due to fatal ILD, compared to primary PM, and establishing therapeutic strategy for ILD may improve the survival in the patient population.
Journal ArticleDOI

Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis

TL;DR: It is confirmed that CADM in addition to DM was associated with high rates of malignancy among the authors' patient cohort, and these features were independent predictive factors for developing malignancies in multiple logistic regression analysis.
Journal ArticleDOI

Methotrexate-induced pulmonary injury: serial CT findings.

TL;DR: CT features of MTX-induced pulmonary injury were variable and included diffuse parenchymal opacification, reticular opacities, and centrilobular nodules, which usually responded quickly to treatment; however, those patients with lung fibrosis at presentation may have worse prognosis.
Journal ArticleDOI

Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II.

TL;DR: Findings suggest that ARBs might have the ability to suppress excessive antigen-specific activation and induction of CTLs promoted by angiotensin II.